Key result
Two doses of BNT162b2 link to stronger and more durable antibody responses than CoronaVac.
Why the study?
The comparative strength and durability of antibody responses to BNT162b2 mRNA vaccine versus CoronaVac inactivated virus vaccine were not well characterized.
Does BNT162b2 mRNA vaccine improve antibody response durability compared to CoronaVac in adults?
Cohort (n=2,780)
Does BNT162b2 mRNA vaccine improve antibody response durability compared to CoronaVac in adults?
BNT162b2 mRNA vaccine elicits stronger and more durable antibody responses than CoronaVac, supporting earlier third doses for CoronaVac recipients.
Antibody data alone should not guide vaccine selection; leaves open correlation with clinical protection against infection.
We studied 2780 adults in Hong Kong who received CoronaVac inactivated virus vaccine (Sinovac) and BNT162b2 mRNA vaccine ("Comirnaty", BioNTech/Fosun Pharma). We compared rates of antibody waning over time using an enzyme-linked immunosorbent assay for spike receptor binding domain and a surrogate virus neutralization test. We found stronger and more durable antibody responses to two doses of the mRNA vaccine, and slightly stronger initial antibody responses to each vaccine in younger adults and women. The weaker and less durable responses following CoronaVac support earlier provision of third doses to persons who previously received two doses of this vaccine.
No takes yet. Share an insight, caveat, or question.
Cowling et al. (2022) conducted a cohort in COVID-19 vaccination (n=2,780). BNT162b2 mRNA vaccine vs. CoronaVac inactivated virus vaccine was evaluated on Rates of antibody waning over time. Two doses of the BNT162b2 mRNA vaccine produced stronger and more durable antibody responses compared to the CoronaVac vaccine.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: